Inflammation and angiotensin II

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 6, 2003, Pages 881-900

  Suzuki, Yusuke ^a   Ruiz Ortega, Marta ^a   Lorenzo, Oscar ^a   Ruperez, Monica ^a   Esteban, Vanesa ^a   Egido, Jesus ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Adhesion molecule; Chemokine; Fibrosis; Permeability; Transcription factor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BOSENTAN; CELL ADHESION MOLECULE; CHEMOKINE; CYCLOSPORIN A; CYTOSKELETON PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LISINOPRIL; LOSARTAN; PARTHENOLIDE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEASOME INHIBITOR; PYRROLIDINE DITHIOCARBAMATE; VASCULOTROPIN;

BLOOD VESSEL PERMEABILITY; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR DYNAMICS; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; RECEPTOR BLOCKING; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE REGENERATION; TISSUE REPAIR; TRANSCRIPTION REGULATION; URETER OBSTRUCTION;

ANGIOTENSIN II; ANIMALS; CAPILLARY PERMEABILITY; CELL ADHESION; CHEMOKINES; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEUTROPHIL INFILTRATION; PEPTIDYL-DIPEPTIDASE A; PROSTAGLANDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037409417     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00271-6     Document Type: Review

References (208)

1. Adams D.H., Lloyd A.R. Chemokines: leucocyte recruitment and activation cytokines. Lancet. 349:1997;490-495.
2. Asscher A.W., Anson S.G. A vascular permeability factor of renal origin. Nature. 198:1963;1097-1099.
3. Barnes P.J., Karin M. Nuclear factor-κB. A pivotal transcription factor in chronic inflammatory diseases. New England Journal of Medicine. 336:1997;1066-1071.
4. Baylis C., Brenner B.M. Modulation by prostaglandin synthesis inhibitors of the action of exogenous angiotensin II on glomerular ultrafiltration in the rat. Circulation Research. 43:1978;889-898.
5. Beilin L.J., Goldby F.S., Mohring J. High arterial pressure versus humoral factors in the pathogenesis of the vascular lesions of malignant hypertension. Clinical Science and Molecular Medicine. 52:1977;111-117.
6. Bohrer M.P., Deen W.M., Robertson C.R., Brenner B.M. Mechanism of angiotensin II-induced proteinuria in the rat. American Journal of Physiology. 2:1977;F13-F21.
7. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis. New England Journal of Medicine. 331:1994;1286-1292.
8. Border W.A., Noble N.A. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 31:1998;181-188.
9. Border W.A., Noble N.A. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Seminars in Nephrology. 21:2001;563-572.
10. Boyce N.W., Holdsworth S.R. Direct anti-GBM antibody induced alterations in glomerular permselectivity. Kidney International. 30:1986;666-672.
11. Boyce N.W., Holdsworth S.R. Intrarenal hemodynamic alterations induced by anti-GBM antibody. Kidney International. 31:1987;8-14.
12. Brasier A.R., Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension. 27:1996;465-475.
13. Brinson A.E., Harding T., Diliberto P.A., He Y., Li X., Hunter D., Herman B., Earp H.S., Graves L.M. Regulation of a calcium-dependent tyrosine kinase in vascular smooth muscle cells by angiotensin II and platelet-derived growth factor. Dependence on calcium and the actin cytoskeleton. The Journal of Biological Chemistry. 273:1998;1711-1718.
14. Burnier M., Brunner H.R. Angiotensin II receptor antagonists. Lancet. 355:2000;637-645.
15. Bush E., Maeda N., Kuziel W.A., Dawson T.C., Wilcox J.N., DeLeon H., Taylor W.R. CC chemokine receptor 2 is required for macrophage infiltration and vascular hypertrophy in angiotensin II-induced hypertension. Hypertension. 36:2000;360-363.
16. Cao Z., Cooper M.E. Role of angiotensin II in tubulointerstitial injury. Seminars in Nephrology. 21:2001;554-562.
17. Capers Q.IV., Alexander R.W., Lou P., De Leon H., Wilcox J.N., Ishizaka N., Howard A.B., Taylor W.R. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension. 30:1997;1397-1402.
18. Carlos T.M., Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood. 84:1994;2068-2101.
19. Chaturvedi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 351:1998;28-31.
20. Chen X.L., Tummala P.E., Olbrych M.T., Alexander R.W., Medford R.M. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circulation Research. 83:1998;952-959.
21. Cheng Z.J., Vaskonen T., Tikkanen I., Nurminen K., Ruskoaho H., Vapaatalo H., Muller D., Park J.K., Luft F.C., Mervaala E.M. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension. 37:2001;433-439.
22. Chisi J.E., Wdzieczak-Bakala J., Thierry J., Briscoe C.V., Riches A.C. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. Stem Cells. 17:1999;339-344.
23. Chua C.C., Hamdy R.C., Chua B.H. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochimica Biophysica Acta. 1401:1998;187-194.
24. Clozel M., Kuhn H., Hefti F., Baumgartner H.R. Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension. 18:1991;132-141.
25. Collares-Buzato C.B., Jepson M.A., Simmons N.L., Hirst B.H. Increased tyrosine phosphorylation causes redistribution of adherens junction and tight junction proteins and perturbs paracellular barrier function in MDCK epithelia. European Journal of Cell Biology. 76:1998;85-92.
26. Connolly D.T., Heuvelman D.M., Nelson R., Olander J.V., Eppley B.L., Delfino J.J., Siegel N.R., Leimgruber R.M., Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. Journal of Clinical Investigation. 84:1989;1470-1478.
27. Constantinescu C.S., Goodman D.B., Ventura E.S. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunology Letters. 62:1998;25-31.
28. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Oliveira-dos-Santos A.J., Da Costa J., Zhang L., Pei Y., Scholey J., Ferrario C.M., Manoukian A.S., Chappell M.C., Beckx P.H., Yagil Y., Penninger J.M. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 417:2002;822-828.
29. Cuthbert M.F., Peart W.S. Studies on the identity of a vascular permeability factor of renal origin. Clinical Science. 38:1970;309-325.
30. Daugherty A., Manning M.W., Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. Journal of Clinical Investigation. 105:2000;1605-1612.
31. Dechend R., Fiebler A., Lindschau C., Bischoff H., Muller D., Park J.K., Dietz R., Haller H., Luft F.C. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. American Journal of Hypertension. 14:2001;55S-61S.
32. Delbaere A., Bergmann P.J., Gervy-Decoster C., Staroukine M., Englert Y. Angiotensin II immunoreactivity is elevated in ascites during severe ovarian hyperstimulation syndrome: implications for pathophysiology and clinical management. Fertility and Sterility. 62:1994;731-737.
33. Deodhar S.D., Cuppage F.E., Gableman E. Studies on the mechanisms of experimental proteinuria induced by renin. Journal of Experimental Medicine. 120:1964;677-690.
34. Diet F., Pratt R.E., Berry G.J., Momose N., Gibbons G.H., Dzau V.J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation. 94:1996;2756-2767.
35. Dol F., Martin G., Staels B., Mares A.M., Cazaubon C., Nisato D., Bidouard J.P., Janiak P., Schaeffer P., Herbert J.M. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. Journal of Cardiovascular Pharmacology. 38:2001;395-405.
36. Dominguez-Jimenez C., Yanez-Mo M., Carreira A., Tejedor R., Gonzalez-Amaro R., Alvarez V., Sanchez-Madrid F. Involvement of alpha3 integrin/tetraspanin complexes in the angiogenic response induced by angiotensin II. The FASEB Journal. 15:2001;1457-1459.
37. Donadelli R., Abbate M., Zanchi C., Corna D., Tomasoni S., Benigni A., Remuzzi G., Zoja C. Protein traffic activates NF-κB gene signaling and promotes MCP-1-dependent interstitial inflammation. American Journal of Kidney Diseases. 36:2000;1226-1241.
38. Drexler H., Kurz S., Jeserich M., Munzel T., Hornig B. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. American Journal of Cardiology. 76:1995;13E-18E.
39. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. American Journal of Pathology. 146:1995;1029-1039. (Review).
40. Dzau V.J., Gonzalez D., Kaempfer C., Dubin D., Wintroub B.U. Human neutrophils release serine proteases capable of activating prorenin. Circulation Research. 60:1987;595-601.
41. Eddy A.A. Molecular insights into renal interstitial fibrosis. Journal of the American Society of Nephrology. 7:1996;2495-2508.
42. Egido J. Vasoactive hormones and renal sclerosis. Kidney International. 49:1996;578-597.
43. Eisenbach G.M., Liew J.B., Boylan J.W., Manz N., Muir P. Effect of angiotensin on the filtration of protein in the rat kidney. Kidney International. 8:1975;80-87.
44. Elchalal U., Schenker J.G. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Human Reproduction. 12:1997;1129-1137.
45. Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Reviews. 13:1992;18-32. (Review).
46. Ferri C., Desideri G., Baldoncini R., Bellini C., De Angelis C., Mazzocchi C., Santucci A. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes. 47:1998;660-667.
47. Fukuhara M., Geary R.L., Diz D.I., Gallagher P.E., Wilson J.A., Glazier S.S., Dean R.H., Ferrario C.M. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension. 35:2000;353-359.
48. Funakoshi Y., Ichiki T., Shimokawa H., Egashira K., Takeda K., Kaibuchi K., Takeya M., Yoshimura T., Takeshita A. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension. 38:2001;100-104.
49. Funatsu H., Yamashita H., Ikeda T., Nakanishi Y., Kitano S., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. American Journal of Ophthalmology. 133:2002;537-543.
50. Funatsu H., Yamashita H., Nakanishi Y., Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. British Journal of Ophthalmology. 86:2002;311-315.
51. Gainer J.V., Morrow J.D., Loveland A., King D.J., Brown N.J. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. New England Journal of Medicine. 339:1998;1285-1292.
52. Gasic S., Wagner O.F., Fasching P., Ludwig C., Veitl M., Kapiotis S., Jilma B. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. American Journal of Hypertension. 12:1999;217-222.
53. Gibbs C.R., Blann A.D., Watson R.D., Lip G.Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation. 103:2001;1746-1751.
54. Gimbrone M.A. Jr., Alexander R.W. Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science. 189:1975;219-220.
55. Goldby F.S., Beilin L.J. How an acute rise in arterial pressure damages arterioles. Electron microscopic changes during angiotensin infusion. Cardiovascular Research. 6:1972;569-584.
56. Gomez R.A., Norling L.L., Wilfong N., Isakson P., Lynch K.R., Hock R., Quesenberry P. Leukocytes synthesize angiotensinogen. Hypertension. 21:1993;470-475.
57. Grafe M., Auch-Schwelk W., Zakrzewicz A., Regitz-Zagrosek V., Bartsch P., Graf K., Loebe M., Gaehtgens P., Fleck E. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circulation Research. 81:1997;804-811.
58. Gruden G., Thomas S., Burt D., Zhou W., Chusney G., Gnudi L., Viberti G. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. Journal of the American Society of Nephrology. 10:1999;730-737.
59. Guazzi M., Marenzi G., Alimento M., Contini M., Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 95:1997;1930-1936.
60. Guba M., Steinbauer M., Buchner M., Frolich D., Farkas S., Jauch K.W., Anthuber M. Differential effects of short-term ACE- and AT1-receptor inhibition on postischemic injury and leukocyte adherence in vivo and in vitro. Shock. 13:2000;190-196.
61. Guijarro C., Egido J. Transcription factor-κB (NF-κB) in renal disease. Kidney International. 59:2001;415-424.
62. Gupta S., Clarkson M.R., Duggan J., Brady H.R. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney International. 58:2000;1389-1399.
63. Hall A. Rho GTPases and the actin cytoskeleton. Science. 279:1998;509-514.
64. Han Y., Runge M.S., Brasier A.R. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circulation Research. 84:1999;695-703.
65. Hansson G.K. Immune mechanisms in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 21:2001;1876-1890.
66. Hernandez-Presa M.A., Bustos C., Ortego M., Tunon J., Ortega L., Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. American Journal of Pathology. 153:1998;1825-1837.
67. Hernandez-Presa M.A., Bustos C., Ortego M., Tunon J., Renedo G., Ruiz-Ortega M., Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 95:1997;1532-1541.
68. Hilgers K.F., Hartner A., Porst M., Mai M., Wittmann M., Hugo C., Ganten D., Geiger H., Veelken R., Mann J.F. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney International. 58:2000;2408-2419.
69. Hisada Y., Sugaya T., Tanaka S., Suzuki Y., Ra C., Kimura K., Fukamizu A. An essential role of angiotensin II receptor type 1α in recipient kidney, not in transplanted peripheral blood leukocytes, in progressive immune-mediated renal injury. Laboratory Investigation. 81:2001;1243-1251.
70. Hisada Y., Sugaya T., Yamanouchi M., Uchida H., Fujimura H., Sakurai H., Fukamizu A., Murakami K. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. Journal of Clinical Investigation. 103:1999;627-635.
71. Hoshida S., Yamashita N., Kawahara K., Kuzuya T., Hori M. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms. Circulation. 99:1999;434-440.
72. Hutchison F.N., Cui X., Webster S.K. The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin. Journal of the American Society of Nephrology. 6:1995;1216-1222.
73. Ichikawa I., Harris R.C. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney International. 40:1991;583-596.
74. Kagami S., Border W.A., Miller D.E., Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. Journal of Clinical Investigation. 93:1994;2431-2437.
75. Kaplan M., Aviram M., Knopf C., Keidar S. Angiotensin II reduces macrophage cholesterol efflux: a role for the AT1 receptor but not for the ABC1 transporter. Biochemical and Biophysical Research Communication. 290:2002;1529-1534.
76. Kasiske B.L., Kalil R.S., Ma J.Z., Liao M., Keane W.F. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Annals of Internal Medicine. 118:1993;129-138.
77. Kataoka C., Egashira K., Inoue S., Takemoto M., Ni W., Koyanagi M., Kitamoto S., Usui M., Kaibuchi K., Shimokawa H., Takeshita A. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 39:2002;245-250.
78. Kato S., Luyckx V.A., Ots M., Lee K.W., Ziai F., Troy J.L., Brenner B.M., MacKenzie H.S. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney International. 56:1999;1037-1048.
79. Keane W.F., Raij L. Relationship among altered glomerular barrier permselectivity, angiotensin II, and mesangial uptake of macromolecules. Laboratory Investigation. 52:1985;599-604.
80. Kiarash A., Pagano P.J., Tayeh M., Rhaleb N.E., Carretero O.A. Upregulated expression of rat heart intercellular adhesion molecule-1 in angiotensin II but not phenylephrine-induced hypertension. Hypertension. 37:2001;58-65.
81. Kim J.A., Berliner J.A., Nadler J.L. Angiotensin II increases monocyte binding to endothelial cells. Biochemical and Biophysical Research Communication. 226:1996;862-868.
82. Klahr S., Morrissey J.J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney International. 75:2000;S7-S14.
83. Klickstein L.B., Kaempfer C.E., Wintroub B.U. The granulocyte-angiotensin system. Angiotensin I-converting activity of cathepsin G. The Journal of Biological Chemistry. 257:1982;15042-15046.
84. Kranzhofer R., Browatzki M., Schmidt J., Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochemical and Biophysical Research Communication. 257:1999;826-828.
85. Krejcy K., Eichler H.G., Jilma B., Kapiotis S., Wolzt M., Zanaschka G., Gasic S., Schutz W., Wagner O. Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. Canadian Journal of Physiology and Pharmacology. 74:1996;9-14.
86. Kunert-Radek J., Stepien H., Komorowski J., Pawlikowski M. Stimulatory effect of angiotensin II on the proliferation of mouse spleen lymphocytes in vitro is mediated via both types of angiotensin II receptors. Biochemical and Biophysical Research Communication. 198:1994;1034-1039.
87. Kupatt C., Habazettl H., Zahler S., Weber C., Becker B.F., Messmer K., Gerlach E. ACE-inhibition prevents postischemic coronary leukocyte adhesion and leukocyte-dependent reperfusion injury. Cardiovascular Research. 36:1997;386-395.
88. Kurihara H., Anderson J.M., Farquhar M.G. Increased Tyr phosphorylation of ZO-1 during modification of tight junctions between glomerular foot processes. American Journal of Physiology. 268:1995;F514-F524.
89. Lapinski R., Perico N., Remuzzi A., Sangalli F., Benigni A., Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. Journal of the American Society of Nephrology. 7:1996;653-660.
90. Lapteva N., Nieda M., Ando Y., Ide K., Hatta-Ohashi Y., Dymshits G., Ishikawa Y., Juji T., Tokunaga K. Expression of renin-angiotensin system genes in immature and mature dendritic cells identified using human cDNA microarray. Biochemical and Biophysical Research Communication. 285:2001;1059-1065.
91. Larsson P.T., Schwieler J.H., Wallen N.H. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagulation & Fibrinolysis. 11:2000;61-69.
92. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
93. Linz W., Wiemer G., Gohlke P., Unger T., Scholkens B.A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacological Reviews. 47:1995;25-49.
94. Lorenzo O., Ruiz-Ortega M., Ruperez M., Suzuki Y., Esteban V., Blanco J., Egido J. Role of NF-κB in AngII-induced renal damage. Studies in AT1 knockout mice with unilateral ureteral obstruction. Journal of the American Society of Nephrology. 13:2002;346A.
95. Luft F.C., Mervaala E., Muller D.N., Gross V., Schmidt F., Park J.K., Schmitz C., Lippoldt A., Breu V., Dechend R., Dragun D., Schneider W., Ganten D., Haller H. Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension. 33:1999;212-218.
96. Ma L.J., Fogo A.B. Role of angiotensin II in glomerular injury. Seminars in Nephrology. 21:2001;544-553.
97. Macconi D., Ghilardi M., Bonassi M.E., Mohamed E.I., Abbate M., Colombi F., Remuzzi G., Remuzzi A. Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats. Journal of the American Society of Nephrology. 11:2000;477-489.
98. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circulation Research. 83:1998;1182-1191.
99. Mattana J., Sankaran R.T., Singhal P.C. Repetitive mechanical strain suppresses macrophage uptake of immunoglobulin G complexes and enhances cyclic adenosine monophosphate synthesis. American Journal of Pathology. 147:1995;529-540.
100. Mattana J., Singhal P.C. Effects of atrial natriuretic peptide and cGMP on uptake of IgG complexes by macrophages. American Journal of Physiology. 265:1993;C92-C98.
101. Mayer G., Lafayette R.A., Oliver J., Deen W.M., Myers B.D., Meyer T.W. Effects of angiotensin II receptor blockade on remnant glomerular permselectivity. Kidney International. 43:1993;346-353.
102. McClure N., Healy D.L., Rogers P.A., Sullivan J., Beaton L., Haning R.V. Jr., Connolly D.T., Robertson D.M. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 344:1994;235-236.
103. Mene P., Fais S., Cinotti G.A., Pugliese F., Luttmann W., Thierauch K.H. Regulation of U-937 monocyte adhesion to cultured human mesangial cells by cytokines and vasoactive agents. Nephrology, Dialysis, and Transplantation. 10:1995;481-489.
104. Mervaala E., Muller D.N., Park J.K., Dechend R., Schmidt F., Fiebeler A., Bieringer M., Breu V., Ganten D., Haller H., Luft F.C. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension. 35:2000;360-366.
105. Mervaala E.M., Muller D.N., Park J.K., Schmidt F., Lohn M., Breu V., Dragun D., Ganten D., Haller H., Luft F.C. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 33:1999;389-395.
106. Mezzano S.A., Ruiz-Ortega M., Egido J. Angiotensin II and renal fibrosis. Hypertension. 38:2001;635-638.
107. Michell, R. N., & Cotran, R. S. (1999). Acute and chronic inflammation. In R. S. Cotran, V. Kumar, & T. Collins (Eds.), Pathologic basis of disease (6th ed.) (pp. 50-112). Philadelphia: WB Saunders.
108. Miyamoto S., Teramoto H., Coso O.A., Gutkind J.S., Burbelo P.D., Akiyama S.K., Yamada K.M. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. Journal of Cell Biology. 131:1995;791-805.
109. Molloy C.J., Taylor D.S., Weber H. Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. The Journal of Biological Chemistry. 268:1993;7338-7345.
110. Morrissey J.J., Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. American Journal of Physiology. 274:1998;F580-F586.
111. Muller D.N., Dechend R., Mervaala E.M., Park J.K., Schmidt F., Fiebeler A., Theuer J., Breu V., Ganten D., Haller H., Luft F.C. NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 35:2000;193-201.
112. Muller D.N., Heissmeyer V., Dechend R., Hampich F., Park J.K., Fiebeler A., Shagdarsuren E., Theuer J., Elger M., Pilz B., Breu V., Schroer K., Ganten D., Dietz R., Haller H., Scheidereit C., Luft F.C. Aspirin inhibits NF-κB and protects from angiotensin II-induced organ damage. The FASEB Journal. 15:2001;1822-1824.
113. Muller D.N., Mervaala E.M., Schmidt F., Park J.K., Dechend R., Genersch E., Breu V., Loffler B.M., Ganten D., Schneider W., Haller H., Luft F.C. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension. 36:2000;282-290.
114. Nakamura S., Nakamura I., Ma L., Vaughan D.E., Fogo A.B. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney International. 58:2000;251-259.
115. Nataraj C., Oliverio M.I., Mannon R.B., Mannon P.J., Audoly L.P., Amuchastegui C.S., Ruiz P., Smithies O., Coffman T.M. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. Journal of Clinical Investigation. 104:1999;1693-1701.
116. Nguyen G., Delarue F., Burcklé C., Bouzhir L., Giller T., Sraer J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. Journal of Clinical Investigation. 109:2002;1417-1427.
117. Nicoletti A., Michel J.B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovascular Research. 41:1999;532-543.
118. Nikolic-Paterson D.J., Lan H.Y., Hill P.A., Atkins R.C. Macrophages in renal injury. Kidney International. Supplement. 45:1994;S79-S82.
119. Okamura A., Rakugi H., Ohishi M., Yanagitani Y., Takiuchi S., Moriguchi K., Fennessy P.A., Higaki J., Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. Journal of Hypertension. 17:1999;537-545.
120. Olivetti G., Kithier K., Giacomelli F., Wiener J. Characterization of glomerular permeability and proteinuria in acute hypertension in the rat. Kidney International. 25:1984;599-607.
121. Ortego M., Bustos C., Hernandez-Presa M.A., Tunon J., Diaz C., Hernandez G., Egido J. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 147:1999;253-261.
122. Otani A., Takagi H., Oh H., Suzuma K., Matsumura M., Ikeda E., Honda Y. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Investigations in Ophthalmology and Visceral Sciences. 41:2000;1192-1199.
123. Otani A., Takagi H., Suzuma K., Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circulation Research. 82:1998;619-628.
124. Owen C.A., Campbell E.J. Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition. Journal of Immunology. 160:1998;1436-1443.
125. Park J.K., Fiebeler A., Muller D.N., Mervaala E.M., Dechend R., Abou-Rebyeh F., Luft F.C., Haller H. Lacidipine inhibits adhesion molecule and oxidase expression independent of blood pressure reduction in angiotensin-induced vascular injury. Hypertension. 39:2002;685-689.
126. Park J.K., Muller D.N., Mervaala E.M., Dechend R., Fiebeler A., Schmidt F., Bieringer M., Schafer O., Lindschau C., Schneider W., Ganten D., Luft F.C., Haller H. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney International. 58:2000;1420-1430.
127. Pastore L., Tessitore A., Martinotti S., Toniato E., Alesse E., Bravi M.C., Ferri C., Desideri G., Gulino A., Santucci A. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation. 100:1999;1646-1652.
128. Pichler R.H., Franceschini N., Young B.A., Hugo C., Andoh T.F., Burdmann E.A., Shankland S.J., Alpers C.E., Bennett W.M., Couser W.G. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. Journal of the American Society of Nephrology. 6:1995;1186-1196.
129. Pickering G.W., Prinzmetal M. The effect of renin on urine formation. The Journal of Physiology (London). 98:1940;314-335.
130. Piqueras L., Kubes P., Alvarez A., O'Connor E., Issekutz A.C., Esplugues J.V., Sanz M.J. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation. 102:2000;2118-2123.
131. Prasad A., Koh K.K., Schenke W.H., Mincemoyer R., Csako G., Fleischer T.A., Brown M., Selvaggi T.A., Quyyumi A.A. Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. American Heart Journal. J.142:2001;248-253.
132. Pueyo M.E., Gonzalez W., Nicoletti A., Savoie F., Arnal J.F., Michel J.B. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arteriosclerosis, Thrombosis, and Vascular Biology. 20:2000;645-651.
133. Pupilli C., Lasagni L., Romagnani P., Bellini F., Mannelli M., Misciglia N., Mavilia C., Vellei U., Villari D., Serio M. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. Journal of the American Society of Nephrology. 10:1999;245-255.
134. Quaglino D. Jr., Nanney L.B., Kennedy R., Davidson J.M. Transforming growth factor-beta stimulates wound healing. Laboratory Investigation. 63:1990;307-319.
135. Rahman S.T., Lauten W.B., Khan Q.A., Navalkar S., Parthasarathy S., Khan B.V. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). American Journal of Cardiology. 89:2002;686-690.
136. Reddy H.K., Sigusch H., Zhou G., Tyagi S.C., Janicki J.S., Weber K.T. Coronary vascular hyperpermeability and angiotensin II. Journal of Laboratory and Clinical Medicine. 126:1995;307-315.
137. Reilly C.F., Tewksbury D.A., Schechter N.M., Travis J. Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. The Journal of Biological Chemistry. 257:1982;8619-8622.
138. Remuzzi A., Puntorieri S., Battaglia C., Bertani T., Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. Journal of Clinical Investigation. 85:1990;541-549.
139. Ricardo S.D., Levinson M.E., DeJoseph M.R., Diamond J.R. Expression of adhesion molecules in rat renal cortex during experimental hydronephrosis. Kidney International. 50:1996;2002-2010.
140. Rodriguez-Iturbe B., Pons H., Herrera-Acosta J., Johnson R.J. Role of immunocompetent cells in nonimmune renal diseases. Kidney International. 59:2001;1626-1640.
141. Rodriguez-Iturbe B., Pons H., Quiroz Y., Gordon K., Rincon J., Chavez M., Parra G., Herrera-Acosta J., Gomez-Garre D., Largo R., Egido J., Johnson R.J. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney International. 59:2001;2222-2232.
142. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
143. Ruiz-Ortega M., Bustos C., Hernandez-Presa M.A., Lorenzo O., Plaza J.J., Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. Journal of Immunology. 161:1998;430-439.
144. Ruiz-Ortega M., Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney International. 52:1997;1497-1510.
145. Ruiz-Ortega M., Gonzalez S., Seron D., Condom E., Bustos C., Largo R., Gonzalez E., Egido J. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney International. 48:1995;1778-1791.
146. Ruiz-Ortega M., Lorenzo O., Egido J. Angiotensin III increases monocytic chemotactic protein-1 and activates nuclear transcription factor κB and activator protein-1 in cultured mesangial and mononuclear cells. Kidney International. 57:2000;2285-2298.
147. Ruiz-Ortega M., Lorenzo O., Ruperez M., Blanco J., Egido J. Angiotensin II activates nuclear transcription factor κB via AT1 and AT2 receptors in the kidney. American Journal of Pathology. 158:2001;1743-1756.
148. Ruiz-Ortega M., Lorenzo M.O., Ruperez M., König S., Wittig B., Egido J. Role of AT1 and AT2 receptors in angiotensin II-induced nuclear transcription factor κB activation in vascular smooth muscle cells. Circulation Research. 86:2000;1266-1272.
149. Ruiz-Ortega M., Lorenzo O., Ruperez M., Suzuki Y., Egido J. Angiotensin II activates nuclear transcription factor-κB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrology, Dialysis, and Transplantation. 1(Supplement 16):2001;27-33.
150. Ruperez M., Lorenzo O., Blanco-Colio L., Esteban V., Ruiz-Ortega M., Egido J. Intracelular signals involved in angiotensin II-induced fibrosis in vascular damage. Description of a new mediator: the connective tissue growth factor. Circulation. 104:2001;867. (Abstract).
151. Ruperez M., Lorenzo O., Esteban V., Egido J., Ruiz-Ortega M. Angiotensin II increases connective tissue growth factor in the kidney. Journal of the American Society of Nephrology. 12:2001;471A.
152. Saijonmaa O., Nyman T., Kosonen R., Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. American Journal of Physiology: Heart Circulation and Physiology. 280:2001;H885-H891.
153. Salvetti A., Mattei P., Sudano I. Renal protection and antihypertensive drugs: current status. Drugs. 57:1999;665-693.
154. Schalkwijk C.G., Smulders R.A., Lambert J., Donker A.J., Stehouwer C.D. ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. European Journal of Clinical Investigation. 30:2000;853-860.
155. Scharschmidt L.A., Dunn M.J. Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and arginine vasopressin. Journal of Clinical Investigation. 71:1983;1756-1764.
156. Schieffer B., Schieffer E., Hilfiker-Kleiner D., Hilfiker A., Kovanen P.T., Kaartinen M., Nussberger J., Harringer W., Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 101:2000;1372-1378.
157. Schlondorff D., Perez J., Satriano J.A. Differential stimulation of PGE2 synthesis in mesangial cells by angiotensin and A23187. Americal Journal of Physiology. 248:1985;C119-C126.
158. Schramek H., Coroneos E., Dunn M.J. Interactions of the vasoconstrictor peptides, angiotensin II and endothelin-1, with vasodilatory prostaglandins. Seminars in Nephrology. 15:1995;195-204.
159. Schrier D.J., Ripani L.M., Katzenstein A.L., Moore V.L. Role of angiotensin-converting enzyme in Bacille Calmette-Guerin-induced granulomatous inflammation. Increased angiotensin-converting enzyme levels in lung lavage and suppression of inflammation with captopril. Journal of Clinical Investigation. 69:1982;651-657.
160. Shimada K., Yazaki Y. Binding sites for angiotensin II in human mononuclear leukocytes. Journal of Biochemistry (Tokyo). 84:1978;1013-1015.
161. Singh K., Sirokman G., Communal C., Robinson K.G., Conrad C.H., Brooks W.W., Bing O.H., Colucci W.S. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 33:1999;663-670.
162. Singhal P.C., Santiago A., Satriano J., Hays R.M., Schlondorff D. Effects of vasoactive agents on uptake of immunoglobulin G complexes by mesangial cells. American Journal of Physiology. 258:1990;F589-F596.
163. Soejima H., Ogawa H., Yasue H., Kaikita K., Takazoe K., Nishiyama K., Misumi K., Miyamoto S., Yoshimura M., Kugiyama K., Nakamura S., Tsuji I. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. Journal of the American College of Cardiology. 34:1999;983-988.
164. 125I -angiotensin II to rat glomerular basement membranes Journal of Clinical Investigation. 59:1977;69-81.
165. Staddon J.M., Herrenknecht K., Smales C., Rubin L.L. Evidence that tyrosine phosphorylation may increase tight junction permeability. Journal of Cell Science. 108:1995;609-619.
166. Steiner R.W., Blantz R.C. Acute reversal by saralasin of multiple intrarenal effects of angiotensin II. American Journal of Physiology. 237:1979;F386-F391.
167. Strawn W.B., Chappell M.C., Dean R.H., Kivlighn S., Ferrario C.M. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 101:2000;1586-1593.
168. Strawn W.B., Dean R.H., Ferrario C.M. Novel mechanisms linking angiotensin II and early atherogenesis. Journal of Renin, Angiotensin, and Aldosterone System. 1:2000;11-17.
169. Sun Y., Ramires F.J., Zhou G., Ganjam V.K., Weber K.T. Fibrous tissue and angiotensin II. Journal of Molecular and Cellular Cardiology. 29:1997;2001-2012.
170. Sun Y., Zhang J.Q., Zhang J., Ramires F.J. Angiotensin II, transforming growth factor-beta1 and repair in the infarcted heart. Journal of Molecular and Cellular Cardiology. 30:1998;1559-1569.
171. Suzuki Y., Gomez-Gurrero C., Shirato I., Lopez-Franco O., Sanjuan G., Ruiz-Ortega M., Sugaya T., Tomino Y., Ra C., Egido J. Susceptibility to T cell-mediated injury in immune complex disease is linked to local activation of renin-angiotensin system: The role of NF-AT pathway. Journal of Immunology. 169:2002;4136-4146.
172. Suzuki Y., Lopez-Franco O., Gomez-Garre D., Tejera N., Gomez-Guerrero C., Sugaya T., Bernal R., Blanco J., Ortega L., Egido J J. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1. American Journal of Pathology. 159:2001;1895-1904.
173. Suzuki Y., Shirato I., Okumura K., Ravetch J.V., Takai T., Tomino Y., Ra C. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. Kidney International. 54:1998;1166-1174.
174. Swartz S.L., Williams G.H. Angiotensin-converting enzyme inhibition and prostaglandins. American Journal of Cardiology. 49:1982;1405-1409.
175. Taal M.W., Chertow G.M., Rennke H.G., Gurnani A., Jiang T., Shahsafaei A., Troy J.L., Brenner B.M., Mackenzie H.S. Mechanisms underlying renoprotection during renin-angiotensin system blockade. American Journal of Physiology. Renal Physiology. 280:2001;F343-F355.
176. Taal M.W., Zandi-Nejad K., Weening B., Shahsafaei A., Kato S., Lee K.W., Ziai F., Jiang T., Brenner B.M., MacKenzie H.S. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney International. 58:2000;1664-1676.
177. Takemori K., Ito H., Suzuki T. Effects of the AT1 receptor antagonist on adhesion molecule expression in leukocytes and brain microvessels of stroke-prone spontaneously hypertensive rats. American Journal of Hypertension. 13:2000;1233-1241.
178. Tayeh M.A., Scicli A.G. Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells in culture. Proceedings of the Association of American Physicians. 110:1998;412-421.
179. The GISEN Group (1997). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet, 349, 1857-1863.
180. Tipnis S.R., Hooper N.H., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. The Journal of Biological Chemistry. 275:2000;33238-33243.
181. Tonnesen M.G., Klempner M.S., Austen K.F., Wintroub B.U. Identification of a human neutrophil angiotension II-generating protease as cathepsin G. Journal of Clinical Investigation. 69:1982;25-30.
182. Tsutamoto T., Wada A., Maeda K., Mabuchi N., Hayashi M., Tsutsui T., Ohnishi M., Sawaki M., Fujii M., Matsumoto T., Kinoshita M. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. Journal of the American College of Cardiology. 35:2000;714-721.
183. Tsutsumi K., Stromberg C., Saavedra J.M. Characterization of angiotensin II receptor subtypes in the rat spleen. Peptides. 13:1992;291-296.
184. Tummala P.E., Chen X.L., Sundell C.L., Laursen J.B., Hammes C.P., Alexander R.W., Harrison D.G., Medford R.M. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation. 100:1999;1223-1229.
185. Tunon J., Ruiz-Ortega M., Egido J. Regulation of matrix proteins and impact on vascular structure. Current Hypertension Reports. 2:2000;106-113.
186. Turner C.E., Pietras K.M., Taylor D.S., Molloy C.J. Angiotensin II stimulation of rapid paxillin tyrosine phosphorylation correlates with the formation of focal adhesions in rat aortic smooth muscle cells. Journal of Cell Science. 108:1995;333-342.
187. Valentin J.P., Jover B., Maffre M., Bertolino F., Bessac A.M., John G.W. Losartan prevents thromboxane A2/prostanoid (TP) receptor mediated increase in microvascular permeability in the rat. American Journal of Hypertension. 10:1997;1058-1063.
188. Wang Y.X., Martin-McNulty B., Freay A.D., Sukovich D.A., Halks-Miller M., Li W.W., Vergona R., Sullivan M.E., Morser J., Dole W.P., Deng G.G. Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. American Journal of Pathology. 159:2001;1455-1464.
189. Wapstra F.H., Navis G., de Jong P.E., de Zeeuw D. Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis. Journal of the American Society of Nephrology. 11:2000;490-496.
190. Weinstock J.V., Blum A.M. Granuloma macrophages in murine schistosomiasis mansoni generate components of the angiotensisystem. Cellular Immunology. 89:1984;39-45.
191. Weinstock J.V., Ehrinpreis M.N., Boros D.L., Gee J.B. Effect of SQ 14225, an inhibitor of angiotensin I-converting enzyme, on the granulomatous response to Schistosoma mansoni eggs in mice. Journal of Clinical Investigation. 67:1981;931-936.
192. Weinstock J.V., Kassab J.T. Functional angiotensin II receptors on macrophages from isolated liver granulomas of murine Schistosoma mansoni. Journal of Immunology. 132:1984;2598-2602.
193. Weinstock J.V., Kassab J. Chemotactic response of splenic mononuclear cells to angiotensin II in murine schistosomiasis. Journal of Immunology. 137:1986;2020-2024.
194. Wenzel U.O., Abboud H.E. Chemokines and renal disease. American Journal of Kidney Diseases. 26:1995;982-994.
195. Wenzel U.O., Thaiss F., Helmchen U., Stahl R.A., Wolf G. Angiotensin II infusion ameliorates the early phase of a mesangioproliferative glomerulonephritis. Kidney International. 61:2002;1020-1029.
196. Wilkinson-Berka J.L., Kelly D.J., Gilbert R.E. The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. Journal of Vascular Research. 38:2001;527-535.
197. Williams B., Baker A.Q., Gallacher B., Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension. 25:1995;913-917.
198. Wintroub B.U., Klickstein L.B., Watt K.W. A human neutrophil-dependent pathway for generation of angiotensin II. Purification of the product and identification as angiotensin II. Journal of Clinical Investigation. 68:1981;484-490.
199. Wolf G., Neilson E.G. Angiotensin II as a renal growth factor. Journal of the American Society of Nephrology. 3:1993;1531-1540.
200. Wolf G., Schneider A., Helmchen U., Stahl R.A. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Experimental Nephrology. 6:1998;112-120.
201. Wolf G., Wenzel U., Burns K.D., Harris R.C., Stahl R.A., Thaiss F. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney International. 61:2002;1986-1995.
202. Wolf G., Ziyadeh F.N., Thaiss F., Tomaszewski J., Caron R.J., Wenzel U., Zahner G., Helmchen U., Stahl R.A. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. Journal of Clinical Investigation. 100:1997;1047-1058.
203. Wu L.L., Cox A., Roe C.J., Dziadek M., Cooper M.E., Gilbert R.E. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney International. 51:1997;1553-1567.
204. Xie Y., Sakatsume M., Nishi S., Narita I., Arakawa M., Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney International. 60:2001;1645-1657.
205. Yamakawa T., Tanaka S., Numaguchi K., Yamakawa Y., Motley E.D., Ichihara S., Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 35:2000;313-318.
206. Yanagitani Y., Rakugi H., Okamura A., Moriguchi K., Takiuchi S., Ohishi M., Suzuki K., Higaki J., Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension. 33:1999;335-339.
207. Yu X.Q., Wu L.L., Huang X.R., Yang N., Gilbert R.E., Cooper M.E., Johnson R.J., Lai K.N., Lan H.Y. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney International. 58:2000;1469-1480.
208. Zoja C., Donadelli R., Corna D., Testa D., Facchinetti D., Maffi R., Luzzana E., Colosio V., Bertani T., Remuzzi G. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. American Journal of Kidney Diseases. 29:1997;254-264.